SCHEMBL2859201

SCHEMBL2859201

CC(C)(O)N(OC(=O)C(Cc1cc(=O)[nH]c2ccccc12)NC(=O)c1ccc(Cl)cc1)C(C)(C)O

nearest known ligand 0.69

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ UBASH3B Q8TF42 1/20 0.69
▸ TACR1 P25103 6/20 0.49
▸ CCKBR P32239 1/20 0.46
▸ KDM4E B2RXH2 2/20 0.46
▸ ALDH1A1 P00352 2/20 0.46
▸ PKM P14618 1/20 0.46
▸ F11 P03951 2/20 0.45
▸ PPARG P37231 1/20 0.42
▸ LMNA P02545 1/20 0.42
▸ TP53 P04637 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ THRB P10828 1/20 0.42
▸ HDAC3 O15379 1/20 0.41
▸ HDAC4 P56524 1/20 0.41
▸ HDAC1 Q13547 1/20 0.41
▸ HDAC7 Q8WUI4 1/20 0.41
▸ HDAC2 Q92769 1/20 0.41
▸ HDAC10 Q969S8 1/20 0.41
▸ HDAC11 Q96DB2 1/20 0.41
▸ HDAC8 Q9BY41 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16666855 0.87 UBASH3B (0.79) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL3420093 0.87 UBASH3B (0.70) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL16666555 0.85 UBASH3B (0.76) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL17268610 0.84 UBASH3B (0.75) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL16666648 0.84 UBASH3B (0.74) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL16666451 0.84 UBASH3B (0.74) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL16666489 0.84 UBASH3B (0.74) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL16666273 0.83 UBASH3B (0.70) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL9294082 0.83 UBASH3B (0.72) UBASH3BTACR1CCKBRKDM4EALDH1A1
SCHEMBL16666561 0.83 UBASH3B (0.72) UBASH3BTACR1CCKBRKDM4EALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1706383-B1 Amine salt of carbostyril derivative useful for the treatment of, inter alia, gastric ulcer OTSUKA PHARMA CO LTD (JP) 2015-07-22 — — EP disclosed
US-8222276-B2 Amine salt of carbostyril derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-07-17 — — US disclosed
EP-2253619-A1 Amine salt of carbostyril derivative Otsuka Pharmaceutical Co., Ltd. (JP) 2010-11-24 — — EP disclosed
US-20100210684-A1 Amine salt of carbostyril derivative OTSUKA PHARMACEUTICAL CO., LTD. 2010-08-19 — — US disclosed
US-7732611-B2 Amine salt of carbostyril derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-06-08 — — US disclosed
US-20070155787-A1 Amine salt of carbostyril derivative OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-07-05 — — US disclosed
EP-1706383-A1 AMINE SALT OF CARBOSTYRIL DERIVATIVE Otsuka Pharmaceutical Company, Limited (JP) 2006-10-04 — — EP disclosed
WO-2005070892-A1 AMINE SALT OF CARBOSTYRIL DERIVATIVE OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-08-04 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100210684-A1 Amine salt of carbostyril derivative SLC7A1, ARGLU1, JAK1 UBASH3B 1921/4885TACR1 292/4885CCKBR 1431/4885
US-20070155787-A1 Amine salt of carbostyril derivative SLC7A1, ARGLU1, JAK1 UBASH3B 2005/4885TACR1 241/4885CCKBR 1303/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback